Zhengying Pan

3.9k total citations · 2 hit papers
42 papers, 3.0k citations indexed

About

Zhengying Pan is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Zhengying Pan has authored 42 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 16 papers in Genetics and 13 papers in Oncology. Recurrent topics in Zhengying Pan's work include Chronic Lymphocytic Leukemia Research (14 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Click Chemistry and Applications (6 papers). Zhengying Pan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Click Chemistry and Applications (6 papers). Zhengying Pan collaborates with scholars based in China, United States and United Kingdom. Zhengying Pan's co-authors include Lee Honigberg, Richard A. Miller, Joseph J. Buggy, Betty Chang, Douglas H. Thamm, Ashley M. Smith, Mint Sirisawad, Erik Verner, David Loury and Gang Xue and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Zhengying Pan

42 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

2010 1.2k citations Lee Honigberg, Zhengying Pan et al. profile →
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase

2006 517 citations Zhengying Pan, Heleen Scheerens et al. ChemMedChem profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zhengying Pan China	21	1.4k	1.3k	840	702	681	42	3.0k
Kumudha Balakrishnan United States	26	1.5k 1.1×	1.2k 0.9×	893 1.1×	484 0.7×	520 0.8×	52	2.8k
Erik Verner United States	18	899 0.6×	1.3k 1.0×	593 0.7×	545 0.8×	410 0.6×	30	2.5k
Mint Sirisawad United States	17	956 0.7×	1.3k 1.0×	767 0.9×	695 1.0×	334 0.5×	38	2.4k
Juerg Schwaller Switzerland	33	569 0.4×	2.1k 1.6×	844 1.0×	1.2k 1.7×	1.3k 1.9×	66	3.8k
Enrique M. Ocio Spain	41	1.4k 1.0×	2.7k 2.0×	1.1k 1.4×	1.9k 2.8×	2.6k 3.9×	206	5.2k
Kami J. Maddocks United States	30	1.8k 1.3×	813 0.6×	2.1k 2.5×	1.5k 2.2×	479 0.7×	197	3.7k
Judy Lucas United States	34	480 0.3×	2.2k 1.7×	287 0.3×	1000 1.4×	443 0.7×	69	4.1k
Stephen K. Tahir United States	22	344 0.2×	2.4k 1.8×	308 0.4×	980 1.4×	337 0.5×	35	3.3k
Markus Müschen United States	40	814 0.6×	2.0k 1.5×	702 0.8×	1.1k 1.5×	984 1.4×	165	4.3k
Yiguo Hu United States	25	805 0.6×	1.7k 1.3×	190 0.2×	772 1.1×	1.5k 2.2×	89	3.1k

Countries citing papers authored by Zhengying Pan

Since Specialization

Citations

This map shows the geographic impact of Zhengying Pan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhengying Pan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhengying Pan more than expected).

Fields of papers citing papers by Zhengying Pan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhengying Pan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhengying Pan. The network helps show where Zhengying Pan may publish in the future.

Co-authorship network of co-authors of Zhengying Pan

This figure shows the co-authorship network connecting the top 25 collaborators of Zhengying Pan. A scholar is included among the top collaborators of Zhengying Pan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhengying Pan. Zhengying Pan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Rui, et al.. (2023). Development of a cell-permeable adenine-derived probe for capture of nucleotide-binding proteins in living cells. Chinese Chemical Letters. 35(3). 108455–108455. 1 indexed citations

Hao, Chenzhou, et al.. (2023). Optically activated MEK1/2 inhibitors (Opti-MEKi) as potential antimelanoma agents. European Journal of Medicinal Chemistry. 251. 115236–115236. 4 indexed citations

Xue, Gang, et al.. (2023). Development of visible-light-activatable photocaged PROTACs. European Journal of Medicinal Chemistry. 265. 116062–116062. 10 indexed citations

Zheng, Chengyou, Weifen Li, Tahir Ali, et al.. (2023). Ibrutinib Delays ALS Installation and Increases Survival of SOD1G93A Mice by Modulating PI3K/mTOR/Akt Signaling. Journal of Neuroimmune Pharmacology. 18(3). 383–396. 7 indexed citations

Zuo, Yingying, et al.. (2023). Discovery of 2,5-diaminopyrimidine derivatives as the first series of selective monomeric degraders of B-lymphoid tyrosine kinase. European Journal of Medicinal Chemistry. 256. 115460–115460. 1 indexed citations

Zuo, Yingying, et al.. (2021). Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK). European Journal of Medicinal Chemistry. 229. 114051–114051. 4 indexed citations

Liu, Yalu, Lijuan Deng, Lingyan Ping, et al.. (2019). ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma. Cancer Cell International. 19(1). 32–32. 23 indexed citations

Wang, Xueying, Gang Xue, & Zhengying Pan. (2019). Design, synthesis and structure–activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK). European Journal of Medicinal Chemistry. 187. 111918–111918. 8 indexed citations

Xue, Gang, Kun Wang, Danli Zhou, Hanbing Zhong, & Zhengying Pan. (2019). Light-Induced Protein Degradation with Photocaged PROTACs. Journal of the American Chemical Society. 141(46). 18370–18374. 263 indexed citations

10.

Cheng, Xiaoqing, Hao Yuan, Mengjie Zhao, et al.. (2017). Cell cycle-dependent degradation of the methyltransferase SETD3 attenuates cell proliferation and liver tumorigenesis. Journal of Biological Chemistry. 292(22). 9022–9033. 43 indexed citations

11.

Zuo, Yingying, et al.. (2015). A novel 2,5-diaminopyrimidine-based affinity probe for Bruton’s tyrosine kinase. Scientific Reports. 5(1). 16136–16136. 5 indexed citations

12.

Zhou, Yiqing, Tianlin Guo, Guanghui Tang, et al.. (2014). Site-Selective Protein Immobilization by Covalent Modification of GST Fusion Proteins. Bioconjugate Chemistry. 25(11). 1911–1915. 27 indexed citations

13.

Liu, Ting, et al.. (2013). Genetic association between p53 codon 72 polymorphism and risk of cutaneous squamous cell carcinoma. Tumor Biology. 35(4). 3899–3903. 8 indexed citations

14.

Zheng, Jie, et al.. (2012). Reductant-directed formation of PS–PAMAM-supported gold nanoparticles for use as highly active and recyclable catalysts for the aerobic oxidation of alcohols and the homocoupling of phenylboronic acids. Chemical Communications. 48(50). 6235–6235. 66 indexed citations

15.

Zhang, Hongfeng, Bei Ding, Tong Fu, et al.. (2011). Rectal cancer: 3D dynamic contrast-enhanced MRI; correlation with microvascular density and clinicopathological features. La radiologia medica. 116(3). 366–374. 41 indexed citations

16.

Pan, Zhengying. (2008). Bruton's tyrosine kinase as a drug discovery target. Drug News & Perspectives. 21(7). 357–357. 21 indexed citations

17.

Pan, Zhengying, Douglas A. Jeffery, Kareem A. H. Chehade, et al.. (2006). Development of activity-based probes for trypsin-family serine proteases. Bioorganic & Medicinal Chemistry Letters. 16(11). 2882–2885. 54 indexed citations

18.

Pan, Zhengying, Heleen Scheerens, Shyr‐Jiann Li, et al.. (2006). Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase. ChemMedChem. 2(1). 58–61. 517 indexed citations breakdown →

19.

Trost, Barry M., et al.. (2002). Polymer‐Supported C₂‐Symmetric Ligands for Palladium‐Catalyzed Asymmetric Allylic Alkylation Reactions. Angewandte Chemie International Edition. 41(24). 4691–4693. 25 indexed citations

20.

Pan, Zhengying, Bruce L. Zuraw, Chien-Cheng Lung, et al.. (1996). Bradykinin stimulates NF-kappaB activation and interleukin 1beta gene expression in cultured human fibroblasts.. Journal of Clinical Investigation. 98(9). 2042–2049. 131 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact